文献速递肝病消化道肿瘤与早癌

抗病毒治疗时代治愈性治疗后HBV相关肝细胞癌双峰复发模式第二峰的衰减

Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era.
PubMed 文献 · J Hepatol · 2025-06-09

该研究纳入香港威尔士亲王医院2000年10月至2017年7月接受治愈性手术或消融的765例乙型肝炎表面抗原阳性肝细胞癌患者,评估抗病毒治疗对复发的影响。中位无复发生存期为31.1个月(95%CI 26.6-39.4)。抗病毒治疗与改善无复发生存期相关(单因素HR 0.84,95%CI 0.74-0.99,p=0.042;多因素HR 0.86,95%CI 0.72-1.03,p=0.106),基线抗病毒治疗在6个月和12个月界标分析中均显著改善无复发生存期。年代趋势分析显示抗病毒暴露较高的队列中第二复发峰衰减。

要点

  • 抗病毒治疗与HBV相关肝细胞癌治愈性治疗后无复发生存期改善相关(单因素HR 0.84,95%CI 0.74-0.99,p=0.042)。
  • 基线抗病毒治疗在6个月界标分析中改善无复发生存期(HR 0.75,95%CI 0.59-0.96,p=0.019)。
  • 基线抗病毒治疗在12个月界标分析中改善无复发生存期(HR 0.62,95%CI 0.47-0.82,p=0.001)。

核心结论

  • 在接受了治愈性手术或消融的HBV相关肝细胞癌患者中,抗病毒治疗与晚期复发减少相关。
  • 抗病毒治疗可使经典双峰复发模式的第二峰消失。

研究设计与样本

  • 研究纳入2000年10月至2017年7月于香港威尔士亲王医院接受治愈性手术或消融的乙型肝炎表面抗原阳性肝细胞癌患者,共765例。
  • 主要终点为无复发生存期,采用时间依赖生存分析、6个月和12个月界标分析,并按早期队列(2001-2005年)和晚期队列(2011-2015年)进行年代趋势分析。

主要发现

  • 整个队列中位无复发生存期为31.1个月(95%CI 26.6-39.4)。
  • 时间依赖生存分析中,抗病毒治疗与改善无复发生存期相关(单因素HR 0.84,95%CI 0.74-0.99,p=0.042),多因素模型呈相似趋势(HR 0.86,95%CI 0.72-1.03,p=0.106)。
  • 6个月界标多因素分析中,基线抗病毒治疗显著改善无复发生存期(HR 0.75,95%CI 0.59-0.96,p=0.019)。
  • 12个月界标多因素分析中,基线抗病毒治疗显著改善无复发生存期(HR 0.62,95%CI 0.47-0.82,p=0.001)。
  • 年代趋势分析显示,抗病毒暴露较高的队列中第二复发峰衰减。

临床怎么用

  • 作者指出,该研究进一步提供证据强调接受治愈性治疗的肝细胞癌患者坚持抗病毒治疗的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Recurrence in patients with hepatocellular carcinoma (HCC) treated with curative surgery or ablation follows a bimodal pattern, with early recurrence peaking at 6 months to 1 year, and late recurrence peaking at 3 to 4 years. We postulate that the use of antiviral therapy may reduce late recurrence by improving control of chronic inflammation. METHODS: Patients with positive HBsAg and HCC (HBV-related HCC) who received curative surgery or ablation from October 2000 to July 2017 were recruited from Prince of Wales Hospital in Hong Kong. The primary endpoint was recurrence-free survival (RFS). We conducted time-dependent survival analysis and 6-month and 12-month landmark analyses to evaluate the impact of antiviral therapy on overall recurrence and late recurrence, respectively. We also conducted a secular trend analysis by stratifying patients into an early cohort (2001-2005) and a late cohort (2011-2015), representing periods of low and high antiviral usage, respectively, to assess changes in recurrence hazard over time. RESULTS: A total of 765 patients with HBV-related HCC were recruited. Median RFS was 31.1 (95% CI 26.6-39.4) months for the entire cohort. In the time-dependent survival analysis, antiviral therapy was associated with improved RFS in the univariate model (hazard ratio [HR] 0.84, 95% CI 0.74-0.99, p = 0.042), with a similar trend observed in the multivariable model (HR 0.86, 95% CI 0.72-1.03, p = 0.106). Baseline antiviral therapy significantly improved RFS in both the 6-month (HR 0.75, 95% CI 0.59-0.96, p = 0.019) and 12-month (HR 0.62, 95% CI 0.47-0.82, p = 0.001) multivariable landmark analyses. Secular trend analysis revealed attenuation of the second recurrence peak in the cohort with higher antiviral exposure. CONCLUSION: Among patients with HBV-related HCC who underwent curative surgery or ablation, antiviral therapy was associated with a reduction in late recurrence. IMPACT AND IMPLICATIONS: The classical bimodal recurrence pattern of hepatocellular carcinoma following curative treatment was established prior to the widespread use of effective antiviral therapy. It is unclear whether this recurrence pattern is still valid in the era of effective antiviral therapy. The current study shows that antiviral therapy can reduce late recurrence, resulting in loss of the second peak of the classical bimodal recurrence pattern. This study provides further evidence highlighting the importance of adherence to antiviral therapy in patients who received curative treatment for hepatocellular carcinoma.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Chan LL, Chan AWH, Yip TCF, et al. Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era. J Hepatol. 2025. PMID: 40499818. doi:10.1016/j.jhep.2025.05.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。